Home Top Stories Pharma investors must persevere despite challenges, Says Jawa boss

Pharma investors must persevere despite challenges, Says Jawa boss

0
27

 

Pharma investors must persevere despite challenges, Says Jawa boss
Chief Varkey Verghese

Investors in Nigeria’s pharmaceutical manufacturing sector must remain committed to their businesses despite the financial and regulatory challenges confronting the industry, Managing Director of Jawa Pharmaceuticals, Chief Varkey Verghese, has said.

Verghese made the call during a panel discussion titled “Inspiring the Next Generation of CEOs and Founders in Pharmaceutical Manufacturing in Nigeria” at the 8th Nigeria Pharma Manufacturers’ Expo organised by the Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria (PMGMAN) at Harbour Point, Lagos.

Speaking on the theme, Verghese shared his experience of navigating the difficulties involved in building a pharmaceutical manufacturing business, urging existing and prospective industry leaders to remain resilient in the face of challenges rather than abandon their investments.

Recounting his experience, Verghese said he borrowed N20 million when he started his business but faced significant challenges, particularly regulatory requirements, which contributed to mounting financial pressures. Within four years, he said, his accumulated debt had risen to about N80 million.

“I borrowed 20 million when I started and experienced a lot of challenges,” Verghese said, explaining that the difficulties did not force him to abandon the business.

Despite the financial burden, he said the company continued to persevere until the challenges eventually became part of its history. “Despite the challenges, we continued to persevere and today, that experience has become history,” he said.

Verghese also advised prospective investors to carefully consider the pharmaceutical segments they enter, urging them to focus on high-value products rather than areas already characterised by intense competition. He described the painkiller market as highly saturated and warned that competing in such segments could become a difficult race for manufacturers.

“The painkiller segment is highly saturated. It is a rat race. Investors should invest in high-value products,” he said.

The Jawa Pharmaceuticals chief further said the NAFDAC 5+5 policy was helping to improve the environment for local pharmaceutical manufacturing, pointing to the importance of policies that support domestic production and provide manufacturers with greater opportunities to build sustainable businesses.

Meanwhile, Chief Executive Officer of Emzor Pharmaceuticals, Dr Stella Okoli, called for greater government attention to the pharmaceutical manufacturing sector, particularly as local manufacturers continue to contend with challenges affecting the sustainability of domestic production. Okoli commended PMGMAN for bringing industry players together to examine the challenges confronting the sector and identify practical measures for strengthening local pharmaceutical manufacturing.

The panel discussion was part of activities at the 8th Nigeria Pharma Manufacturers’ Expo and provided an opportunity for established industry leaders to share their experiences with the next generation of pharmaceutical entrepreneurs, particularly on investment, resilience, regulation and building sustainable manufacturing businesses in Nigeria.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here